Headlines about Imprimis Pharmaceuticals (NASDAQ:IMMY) have trended somewhat positive on Saturday, Accern Sentiment reports. Accern identifies positive and negative press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Imprimis Pharmaceuticals earned a news sentiment score of 0.13 on Accern’s scale. Accern also gave media coverage about the specialty pharmaceutical company an impact score of 45.6631506372648 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Shares of Imprimis Pharmaceuticals (NASDAQ IMMY) traded down 4.27% during midday trading on Friday, reaching $1.57. 246,846 shares of the company were exchanged. The company’s 50-day moving average price is $1.67 and its 200 day moving average price is $2.75. Imprimis Pharmaceuticals has a 52-week low of $1.40 and a 52-week high of $4.69. The stock’s market capitalization is $31.50 million.
Imprimis Pharmaceuticals (NASDAQ:IMMY) last posted its quarterly earnings data on Thursday, August 10th. The specialty pharmaceutical company reported $0.06 earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.29. The firm had revenue of $6.86 million during the quarter. Imprimis Pharmaceuticals had a negative net margin of 57.07% and a negative return on equity of 242.66%. On average, equities analysts predict that Imprimis Pharmaceuticals will post ($0.86) earnings per share for the current year.
Separately, Zacks Investment Research upgraded shares of Imprimis Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, July 12th.
ILLEGAL ACTIVITY NOTICE: This report was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The original version of this report can be read at https://www.dispatchtribunal.com/2017/10/29/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-imprimis-pharmaceuticals-immy-stock-price.html.
About Imprimis Pharmaceuticals
Imprimis Pharmaceuticals, Inc (Imprimis) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment.
Receive News & Ratings for Imprimis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imprimis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.